XELODA

Breast cancer is the most widespread cancer type in US and Europe women. Breast cancer may develop in 8-9% women during life time. Every year 250 000 new patients are revealed suffering from breast cancer in Europe and 175 000 in the USA and the diseases rate steadily increases every year. Breast cancer is rated second on cancer mortality cases among Europe and US women. About 50% of patients receiving therapy are reported to have metastases. The average probability of survival after metastases detection makes 18- 30 months and may vary depending on the localization of metastases. For example life duration of the patients having visceral metastases can make 6-13 months.
What do you think I felt like when my breast cancer diagnosis was confirmed? I plunged into despair. But my doctor comforted me and told about Xeloda. When I got more into the issue I learned a lot of interesting facts. I gave my consent to receive chemotherapeutics. Systemic treatment with cytostatic agent is a good choice for the patients who are resistant to hormonal treatment or who have fast increasing visceral metastases. The chemotherapy is aimed at reduction of pain syndrome, maintaining of life quality through remission induction and control of rapidity of disease progression. Doctors more often resort to earlier prescription of highly active medications in cancer treatment. Xeloda was created to satisfy the need for a medication which could be safely used on an outpatient basis for treatment of women suffering from neglected breast cancer, progressing after therapy.
Since Xeloda is to be taken orally, it can be used for a long time. Xeloda treatment imitates uninterrupted infusion 5-FU, but is not mated with such expenses, discomfort and complications which usually accompany the uninterrupted infusion treatment. Moreover the unique medication brings about formation of 5-FU in the tumor tissue thereby reducing impact on the healthy tissues and increasing effectiveness of treatment. Xeloda is approved for treatment of women suffering from breast cancer in many countries including USA, Canada, Switzerland, Russia and Australia. The clinical trials have been carried out in 24 medical centers in the USA. Xeloda demonstrated great results in women suffering from breast cancer. The research showed decrease of mortality, high rate of effectiveness and proved the safety of the medicine. Impact of Xeloda on tumor- associated symptoms was assessed at positive clinical dynamic rating scale, which included dynamics of pain intensity, the need for analgesics and general health state parameters.
Xeloda is a quite important medication and an extremely promising trend of treatment of breast cancer and other oncological diseases. Aiming only at the main reason, the disease may be treated without affecting the healthy tissues with Xeloda, thereby improving the quality of life of cancer patients. Xeloda allows prolonging and even saving the lives of oncological patients. Xeloda prevents the growth of network of blood vessels nourishing cancerous cells and blocks formation of the tumor. Usually the tumor is removed surgically. But it is only effective in the early stage of the disease. Treatment of the advanced disease is usually consists in the suppression of the growth of the tumor and alleviation of the associated symptoms.
Breast cancer is ranked first among all the oncological diseases in women and is one of the main reasons for female mortality in the world.
After completion of Xeloda course I have made sure that it works. All my hopes justified and all my dreary thoughts have gone. If it worked for me, I think it will be good for other women too.